Publications

265 publications

Enter search criteria

Fill in keyword(s) to narrow your search.

Period from
to

Enter a start and/or end date here, using the following format: DD-MM-YYYY.

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by: Date / Relevance

Denosumab (XGEVA) for the 'prevention of skeletal-related events in adults with bone metastases from solid tumours’

In the treatment of bone metastases from solid tumors, the therapeutic value of s.c. denosumab is comparable with that of i.v. ...

Report | 23-01-2012

Everolimus (Votubia) for the indication 'treatment of patients aged 3 years and older with subependymal giant cell astrocytoma associated with tuberous sclerosis complex

The use of everolimus for the treatment of patients aged 3 years and older with subependymal giant cell astrocytomas (SEGA) ...

Report | 23-01-2012

Background report assessing whether occipital neurostimulation for chronic cluster headache complies with established medical science and medical practice

Occipital neurostimulation in cases of refractory chronic cluster headaches does not comply with the ‘established medical science ...

Report | 22-11-2011

Transcatheter aortic valve replacement

In the opinion of CVZ, TAVI (transcatheter aortic valve implantation) is care that complies with established medical science and ...

Report | 26-10-2011

Infliximab (Remicade) for the indication 'plaque psoriasis’

Infliximab and adalimumab, etanercept and ustekinumab are of equal therapeutic value in the treatment of adults suffering from ...

Report | 24-10-2011

Infliximab (Remicade) for the indication 'colitis ulcerosa’

For the treatment of moderate to severe cases of colitis ulcerosa, in comparison with ciclosporin, infliximab has a therapeutic ...

Report | 24-10-2011

Nursing in AWBZ institutions

The questions focus on nursing care that is necessary in connection with that medical specialist care. CVZ acknowledges that the ...

Report | 29-09-2011

Sunitinib malate (Sutent) for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours

For the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression ...

Report | 26-09-2011

Preferential policy towards biological drugs

CVZ regards biological drugs as therapeutically interchangeable if they are designated as "similar" after being registered by the ...

Report | 26-09-2011

Eslicarbazepine (Zebinix) for the ‘adjunctive treatment of partial onset seizures with or without secondary generalisation in adults with epilepsy’

The therapeutic value of eslicarbazepine as an adjunctive treatment for partial epilepsy is comparable with that of oxcarbazepine.

Report | 26-09-2011